MX2022001303A - Heterocyclic compound. - Google Patents

Heterocyclic compound.

Info

Publication number
MX2022001303A
MX2022001303A MX2022001303A MX2022001303A MX2022001303A MX 2022001303 A MX2022001303 A MX 2022001303A MX 2022001303 A MX2022001303 A MX 2022001303A MX 2022001303 A MX2022001303 A MX 2022001303A MX 2022001303 A MX2022001303 A MX 2022001303A
Authority
MX
Mexico
Prior art keywords
group
binding site
formula
represented
optionally substituted
Prior art date
Application number
MX2022001303A
Other languages
Spanish (es)
Inventor
Naomi Kitamoto
Yoshihide Tomata
Yusuke Tominari
Kanae Gamo
Original Assignee
Fimecs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fimecs Inc filed Critical Fimecs Inc
Publication of MX2022001303A publication Critical patent/MX2022001303A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

To provide a novel heterocyclic compound which has an effect of inducing the degradation of IRAK-M protein and which is expected to be useful for preventing or treating cancer, fibrosis, infectious diseases, etc., and a medicine comprising the same. The invention provides a compound represented by formula (I), where the IRAK-M binder (M) is represented by formula (II) [in formula (II): Y represents CH or N; R01 represents H or Me; R03 is a group represented by structural formula BB (where: * represents a binding site to O; ** represents a binding site to A; and n is an integer of 0-2); A is a group represented by structural formula CC (where R05's independently represent a hydrogen atom or a C1-6 alkyl group) or *-SO2-*; R04 is a group represented by structural formula DD (where: * represents a binding site to A; and ** represents a binding site to the linker), an optionally substituted C1-6 alkylene group, an optionally substituted C3-10 cycloalkylene group, an optionally substituted C6-14 arylene group or a bond; and the arrow represents a bond to the linker (L)], or a pharmaceutically acceptable salt thereof.
MX2022001303A 2019-07-31 2020-07-31 Heterocyclic compound. MX2022001303A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019141700A JP2021024787A (en) 2019-07-31 2019-07-31 Heterocyclic compound
PCT/JP2020/029590 WO2021020586A1 (en) 2019-07-31 2020-07-31 Heterocyclic compound

Publications (1)

Publication Number Publication Date
MX2022001303A true MX2022001303A (en) 2022-03-02

Family

ID=74228910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001303A MX2022001303A (en) 2019-07-31 2020-07-31 Heterocyclic compound.

Country Status (9)

Country Link
JP (1) JP2021024787A (en)
KR (1) KR20220042136A (en)
CN (1) CN114729004A (en)
AU (1) AU2020321513A1 (en)
BR (1) BR112022001437A2 (en)
CA (1) CA3148955A1 (en)
MX (1) MX2022001303A (en)
TW (1) TW202120511A (en)
WO (1) WO2021020586A1 (en)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271980B2 (en) 2009-08-03 2016-03-01 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
US9090624B2 (en) 2011-08-04 2015-07-28 Allergan, Inc. Aromatic bycyclic derivatives as CXCR4 receptor modulators
JP5934986B2 (en) 2011-09-07 2016-06-15 公益財団法人ヒューマンサイエンス振興財団 Apoptosis-inhibiting protein ligand-estrogen receptor ligand hybrid compound, estrogen receptor degradation inducer using the same, and preventive and therapeutic agent for breast cancer, cervical cancer or ovarian cancer
CN103242341B (en) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 Thieno-2,4 substituted pyrimidines compounds and pharmaceutical composition thereof and application
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2018105094A (en) 2015-07-13 2019-08-14 Арвинас, Инк. ALANINE-BASED PROTEOLYSIS MODULATORS AND RELATED APPLICATION METHODS
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6899993B2 (en) 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 Heterocyclic compound
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
AU2018396142A1 (en) 2017-12-26 2020-07-16 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP6709817B2 (en) 2018-03-27 2020-06-17 矢崎総業株式会社 connector
CN112533898A (en) * 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 Heterocyclic compounds

Also Published As

Publication number Publication date
KR20220042136A (en) 2022-04-04
CA3148955A1 (en) 2021-02-04
AU2020321513A1 (en) 2022-02-24
JP2021024787A (en) 2021-02-22
TW202120511A (en) 2021-06-01
BR112022001437A2 (en) 2022-05-24
WO2021020586A1 (en) 2021-02-04
CN114729004A (en) 2022-07-08

Similar Documents

Publication Publication Date Title
CY1117576T1 (en) NUCLEOTIC PRODUCTS
CY1124239T1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
JP2010523684A5 (en)
NZ701478A (en) Pyrrolobenzodiazepines
MY177250A (en) Novel nicotinamide derivative or salt thereof
EA200601350A1 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS
BRPI0416656A (en) pyrrolopyrimidine compounds useful in cancer treatment
CO6310968A2 (en) DERIVATIVES OF 3,5-DIAMINO REPLACED-N-TETRAHYDROPIRIMIDIN / IMIDAZOLIN / DIAZEPAM-2-ILIDENPIRAZIN-2-CARBOXAMIDE, USEFUL AS BLOCKERS OF THE ACTIVITY OF THE EPITELIAL SODIUM CHANNEL (ENAC)
BRPI0813244B8 (en) compounds derived from pyrazinone, compositions comprising said compounds, use of the compounds in the treatment of lung diseases and intermediate compound
PH12014501804A1 (en) Cycloalkane derivative
MXPA05011150A (en) (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMERaCOES DISEASE.
NO20080955L (en) Quinoline derivatives as antibacterial agents
NZ701290A (en) Pyrrolobenzodiazepines
EA200500814A1 (en) DERIVATIVES OF PYRROPOLYMIDININE
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
CY1115262T1 (en) TRPV1 COMPETITORS AND THEIR USES
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
TW200806299A (en) Treatment of pain
EA201391263A1 (en) COMBINED THERAPIES OF HEMATOLOGICAL TUMORS
MY142652A (en) Quinuclidine derivatives binding to muscarinic m3 receptors
MX2009011601A (en) Therapeutic agents useful for treating pain.
TW200639159A (en) Treatment of pain
MX2009012613A (en) Heteroaryl substituted thiazoles and their use as antiviral agents.
RU2017118792A (en) ANTIBODY CONJUGATES TO STAPHYLOCOCCUS AUREUS WITH RIFAMICINE AND THEIR APPLICATION